Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene CorpfiledCriticalCelgene Corp
Priority to CL2021002846ApriorityCriticalpatent/CL2021002846A1/en
Publication of CL2021002846A1publicationCriticalpatent/CL2021002846A1/en
Se proporcionan en la presente métodos para tratar enfermedades y trastornos que responden a la inhibición de PDE4 que comprende administrar apremilast y un inhibidor de Tyk2 a un sujeto. También se proporcionan en la presente composiciones farmacéuticas que comprenden apremilast y un inhibidor de Tyk2.Provided herein are methods of treating diseases and disorders responsive to PDE4 inhibition comprising administering apremilast and a Tyk2 inhibitor to a subject. Also provided herein are pharmaceutical compositions comprising apremilast and a Tyk2 inhibitor.
CL2021002846A2021-10-292021-10-29
Combination therapies comprising apremilast and tyk2 inhibitors
CL2021002846A1
(en)
A pharmaceutical combination comprising a b-raf inhibitor and a histone deacetylase inhibitor and their use in the treatment of proliferative diseases.